MedPath

UNIVERSITY OF UTAH

UNIVERSITY OF UTAH logo
🇺🇸United States
Ownership
Private
Established
1850-02-28
Employees
10K
Market Cap
-
Website
http://www.utah.edu

Clinical Trials

914

Active:49
Completed:515

Trial Phases

6 Phases

Early Phase 1:48
Phase 1:106
Phase 2:133
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (704 trials with phase data)• Click on a phase to view related trials

Not Applicable
362 (51.4%)
Phase 2
133 (18.9%)
Phase 1
106 (15.1%)
Early Phase 1
48 (6.8%)
Phase 4
34 (4.8%)
Phase 3
21 (3.0%)

N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Not Applicable
Not yet recruiting
Conditions
B-cell Non Hodgkin Lymphoma
Interventions
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
University of Utah
Target Recruit Count
13
Registration Number
NCT07049432
Locations
🇺🇸

Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.

Not Applicable
Not yet recruiting
Conditions
HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Squamous Cell Carcinoma
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
University of Utah
Target Recruit Count
42
Registration Number
NCT07044635
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

SAVE Trial: SAfe Opioid Use Video Education

Not Applicable
Not yet recruiting
Conditions
Breast Reconstruction
Breast Cancer
First Posted Date
2025-07-01
Last Posted Date
2025-07-03
Lead Sponsor
University of Utah
Target Recruit Count
68
Registration Number
NCT07044583
Locations
🇺🇸

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

Serious Game to Promote Transition Readiness Skills for Patients With Congenital Heart Disease

Not Applicable
Not yet recruiting
Conditions
Serious Games
Congenital Heart Defect
Transition-age Youth
Transition to Adult Care
Congenital Heart Disease in Adolescence
Patient Centered Care
First Posted Date
2025-06-29
Last Posted Date
2025-06-29
Lead Sponsor
University of Utah
Target Recruit Count
150
Registration Number
NCT07042334
Locations
🇺🇸

Primary Children's Hospital and University of Utah Health, Salt Lake City, Utah, United States

Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer

Not Applicable
Not yet recruiting
Conditions
Prostate Cancer
Metastatic Prostate Cancer
Androgen Deprivation Therapy
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
University of Utah
Target Recruit Count
74
Registration Number
NCT07032584
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 183
  • Next

News

Breakthrough: First Successful Stem Cell Transplant Using Deceased Donor for Blood Cancer Treatment

Huntsman Cancer Institute at the University of Utah has achieved the first-ever allogeneic stem cell transplant using cells from a deceased donor, potentially revolutionizing treatment access for blood cancer patients.

Air Pollution During Pregnancy Linked to Severe Neonatal Health Risks and Brain Development Issues

Exposure to air pollution during pregnancy, particularly in the final month, increases newborn risk of requiring intensive care treatment by up to 35%, according to recent research published in Scientific Reports.

Phase III Trial Shows Hypofractionated Radiation Therapy Safe and Effective for Breast Cancer Patients with Reconstruction

The RT CHARM phase III trial demonstrated that shortened radiation therapy (3 weeks) is noninferior to conventional 5-week treatment for breast cancer patients undergoing reconstruction after mastectomy.

Weight Loss Drugs Wegovy and Zepbound Not Cost-Effective at Current Prices, Study Finds

Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.

Cooling Therapy Shows No Benefit for Preterm Infants with Brain Injury, NIH Study Finds

A large NIH-funded clinical trial reveals that therapeutic hypothermia, previously successful in term infants, offers no protection against death or disability in preterm infants with hypoxic ischemic encephalopathy.

Higher-Dose, Two-Session Vaginal Brachytherapy Proves Effective for Endometrial Cancer Treatment

A randomized clinical trial led by Huntsman Cancer Institute demonstrates that two sessions of high-dose vaginal brachytherapy are as effective as standard multiple low-dose treatments for endometrial cancer.

© Copyright 2025. All Rights Reserved by MedPath